83 / 89
83
Amouri A, Louzir H, Dellagi K, Abdeladhim AB. Blood
2008;111:1805-10.
45.
Regelink JC, van Roessel CH, van Galen KP,
Ossenkoppele GJ, Huijgens PC, Zweegman S. Long-term
follow-up of tandem autologous stem-cell transplantation
in multiple myeloma. J Clin Oncol 2010;28:e741-3.
46.
Björkstrand BB, Ljungman P, Svensson H, Hermans J,
Alegre A, Apperley J, et al. Allogeneic bone marrow
transplantation
versus
autologous
stem
cell
transplantation in multiple myeloma: a retrospective case-
matched study from the European Group for Blood and
Marrow Transplantation Blood 1996;88:4711-8.
47.
Khaled Y, Mellacheruvu S, Reddy P, Peres E, Mineishi S.
Long-term outcomes following myeloablative allogeneic
transplantation for multiple myeloma compared to
autologous transplantation and the impact of graft-
versus-myeloma effect. Bone Marrow Transplant
2009;44:325-6.
48.
Rosiñol L, Pérez-Simón JA, Sureda A, de la Rubia J, de
Arriba F, Lahuerta JJ, et al. A prospective PETHEMA
study of tandem autologous transplantation versus
autograft followed by reduced-intensity conditioning
allogeneic transplantation in newly diagnosed multiple
myeloma. Blood 2008;112:3591-3.
49.
Björkstrand B, Iacobelli S, Hegenbart U, Gruber A,
Greinix H, Volin L, et al. Tandem autologous/reduced-
intensity conditioning allogeneic stem-cell transplantation
versus autologous transplantation in myeloma: long-term
follow-up. J Clin Oncol 2011;29:3016-22.
50.
Alegre A, Tomás JF, Martínez-Chamorro C, Gil-
Fernández JJ, Fernández-Villalta MJ, Arranz R, et al.
Comparison of peripheral blood progenitor cell
mobilization in patients with multiple myeloma: high-